IBD tied to risk for prostate cancer

  • Burns JJ & et al.
  • Eur Urol
  • 4 Dec 2018

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The risk for any and clinically significant prostate cancer was significant in men with IBD vs age- and race-matched men without IBD.
  • No association was found between IBD and metastatic disease.

Why this matters

  • Data on the association between prostate cancer and IBD are limited.

Study design

  • Study of 1033 patients with IBD and 9306 age- and race-matched men without IBD (control group) who underwent ≥1 PSA screening test.
  • Funding: None.

Key results

  • Median age was 53 years in both groups.
  • Median follow-up time: IBD group, 6.5 years; control group, 4.7 years.
  • At 10 years, men with IBD vs those without IBD showed higher incidence of:
    • prostate cancer (4.4% vs 0.65%; HR, 4.84; P<.001>
    • clinically significant (Gleason score of ≥7) prostate cancer (2.4% vs 0.42%; HR, 4.04; P<.001>
  • The incidence of metastatic prostate cancer was statistically similar between IBD and control groups (0.19% vs 0.03%; P=.061).
  • In patients with IBD, disease duration of >20 years, use of biologic medications, bowel resection, and a diagnosis of ulcerative colitis were not associated with any or clinically significant disease.

Limitations

  • Retrospective design.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit